February 27, 2020 / 11:31 PM / a month ago

BRIEF-Mylan NV Mylan Exec Expects Some Impact From Coronavirus Due To Global Nature Of Business Says Business Exposure In China Is Limited- Conf. Call

Feb 27 (Reuters) - Mylan NV:

* MYLAN EXEC EXPECTS SOME IMPACT FROM CORONAVIRUS DUE TO GLOBAL NATURE OF BUSINESS; SAYS BUSINESS EXPOSURE IN CHINA IS LIMITED- CONF. CALL

* MYLAN EXEC SAYS DOES NOT SEE ANY IMPACT OF FDA INSPECTION OF BIOCON MANUFACTURING PLANT ON COMMERCIALIZATION PLANS FOR INSULIN GLARGINE IN THE U.S.- CONF. CALL

* EXEC SAYS TOO EARLY TO PREDICT ANY COMMERCIAL IMPACT DUE TO THE CORONAVIRUS TO OPERATIONS AROUND THE GLOBE - CONF. CALL

* EXEC SAYS BIOSIMILARS WILL CONTINUE TO BE A GROWTH DRIVER AFTER PFIZER UNIT MERGER- CONF. CALL

* EXEC DOES NOT SEE ANY CORONAVIRUS IMPACT IN NEAR FUTURE; SAYS IF SITUATION CONTINUES OVER NEXT COUPLE OF MONTHS, SEES IMPACT RELATED TO DRUG SHORTAGES- CONF. CALL

* MYLAN EXEC SEEING LOGISTICAL ISSUES DUE TO CORONAVIRUS, BUT NOT SEEING ISSUES WITH PRODUCTION OR PRICE INCREASES OF ACTIVE INGREDIENTS - CONF CALL Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below